Platelets and Vascular Risk: An Option for Treatment
| Autor: | IA Jagroop, Dimitri P. Mikhailidis, Anna I. Kakafika |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
medicine.medical_specialty
Platelet Aggregation Myocardial Infarction Drug Discovery medicine Humans Platelet activation Risk factor Intensive care medicine Stroke Peripheral Vascular Diseases Pharmacology Vascular disease business.industry Thrombosis Platelet Activation medicine.disease Clopidogrel Clinical trial Treatment Outcome Cardiovascular Diseases Anesthesia Glycoprotein IIb/IIIa inhibitors Drug Therapy Combination business Platelet Aggregation Inhibitors medicine.drug |
| Zdroj: | Current Pharmaceutical Design. 13:1669-1683 |
| ISSN: | 1381-6128 |
| DOI: | 10.2174/138161207780831383 |
| Popis: | Epidemiological studies have linked platelet hyperactivity with an increased risk of vascular events. Even more convincing is the evidence from appropriately designed clinical trials showing that antiplatelet agents decrease the risk of vascular events (e.g. myocardial infarction, MI and stroke). These findings are compatible with the known thrombotic action of platelets. A considerable limitation in platelet research is the absence of a reliable, universally accepted marker of platelet activity. Therefore, it is difficult to reliably identify the ‘high risk patient’ and/or evaluate the efficacy of any administered treatment other than by calculating event rates over a period of time. This review will focus on the preventive aspects of antiplatelet intervention while also briefly considering the assessment of platelet hyperactivity and the mechanisms involved in platelet-induced thrombosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|